Clinical Trials Browser

Infliximab × 1 year × Clear all

NCT03819296 2026-03-11

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Colitis, Lung Neoplasms, Urogenital Neoplasms

NCT04438382 2026-02-27

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

Phase 2 Terminated

1 enrolled 1 chart

Other hematologic neoplasm

Hematologic Neoplasms

NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Phase 2 Active not recruiting

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT06646016 2025-12-26

EPIC

Phase 2 Withdrawn

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

Phase 1/2 Active not recruiting

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

NCT00463580 2025-07-08

Infliximab

Phase 4 Completed

60 enrolled 15 charts

Bipolar Disorder, Depression, Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant

NCT02638701 2025-07-08

Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms

Phase 1/2 Recruiting

Aneurysm, Vasculitis, Stroke

NCT02711202 2025-06-04

Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation

Phase NA Completed

20 enrolled 11 charts

Kidney Transplantation

NCT03765450 2025-05-16

PROTOS

Active not recruiting

Colitis, Ulcerative

NCT06136546 2025-05-07

Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

Phase 2 Recruiting

Depression, Depressive Disorder, Major, Inflammation, Cognitive Dysfunction